Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
NCT ID: NCT00483652
Last Updated: 2016-02-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
240 participants
INTERVENTIONAL
2007-05-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Oral Fampridine-SR in Multiple Sclerosis
NCT00127530
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis
NCT00654927
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
NCT00649792
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
NCT01328379
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
NCT00648908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo control
Placebo
placebo (sugar pill)
Fampridine-SR
10 mg b.i.d.
Fampridine-SR
Tablets, 10 mg, twice daily, 9 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fampridine-SR
Tablets, 10 mg, twice daily, 9 weeks
Placebo
placebo (sugar pill)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients must be able to complete two trials of a timed 25 foot walk
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Acorda Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Blight, PhD
Role: STUDY_DIRECTOR
Acorda Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
HOPE Research Institute
Phoenix, Arizona, United States
Neurological Associates
Fayetteville, Arkansas, United States
Alta Bates Summit Medical Center - Research and Education Institute
Berkeley, California, United States
USC, Keck School of Medicine Health Care Consultation Center
Los Angeles, California, United States
UC Davis
Sacramento, California, United States
Yale University MS Center
New Haven, Connecticut, United States
Shepherd Center
Atlanta, Georgia, United States
Consultants in Neurology, Ltd.
Northbrook, Illinois, United States
Indiana University MS Center
Indianapolis, Indiana, United States
Associates in Neurology, PSC
Lexington, Kentucky, United States
Maryland Center for MS
Baltimore, Maryland, United States
Lahey Clinic
Lexington, Massachusetts, United States
The Schapiro Center for MS
Golden Valley, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Advanced Neurology Specialists
Great Falls, Montana, United States
UMDNJ
Newark, New Jersey, United States
Gimbel MS Center at Holy Name Hospital
Teaneck, New Jersey, United States
Jacobs Neurological Institute Buffalo General Hospital
Buffalo, New York, United States
Corinne Goldsmith Dickinson Center for MS
New York, New York, United States
Columbia University Multiple Sclerosis Clinical Care Center
New York, New York, United States
University of Rochester
Rochester, New York, United States
SUNY Stony Brook
Stony Brook, New York, United States
CMC - Neuroscience & Spine Institute, Division of Neurology
Charlotte, North Carolina, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
Wake Forest University, Dept of Neurology, M.S. Research
Winston-Salem, North Carolina, United States
The Center for Neurological Services
Bismarck, North Dakota, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Ohio State University MS Center
Columbus, Ohio, United States
Oregon Health & Science University, MS Center of Oregon, UHS-42
Portland, Oregon, United States
Thomas Jefferson University Physicians
Philadelphia, Pennsylvania, United States
Neurological Research Center, Inc.
Bennington, Vermont, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
MS Center at Evergreen
Kirkland, Washington, United States
CAMC Health Education & Research Institute
Charleston, West Virginia, United States
Center for Neurological Disorders of Aurora, St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Foothills Medical Center
Calgary, Alberta, Canada
University of British Columbia, Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada
River Valley Health c/o Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, Canada
QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site
Halifax, Nova Scotia, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about Fampridine-SR clinical trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-F204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.